Ekr Therapeutics, Inc.

Abbvie Inc.

Facet Biotech Corporation

Abbvie Biotherapeutics Inc.

Abbott Biotherapeutics Corp.

Supriya Gupta

Camellia Zamiri

Michelle Renee Duncan

David Hartley Haas

Norma V Stephens

Ravi Chari

Jijie Gu

Dominic J Ambrosi

Yingchun Li

Jonathan A Hickson

Louie Naumovski

Susan E Lappe

Elizabet Kaisheva

Xianhua Cao

Deanna L Haasch

Norma V Nenonene

Aleni Flores-Nate

Yanli Mi

Malathy Subramanian

Shanti G Duvur

Elizabet A Kaisheva

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Pre-mixed, ready-to-use pharmaceutical compositions

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof

Compositions of an inclusion complex of nicardipine or a pharmaceutically acceptable salt thereof and a sulfoalkylated &#x3b2;-cyclodextrin. The compositions being formulated for parenteral bolus administration to a human subject. The compositions being useful in the treatment of cardiovascular and cerebrovascular disorders.

Compositions of nicardipine and sulfoalkylated &#x3b2;-cyclodextrin

Methods of preparing pre-mixed, ready-to-use pharmaceutical compositions

Disclosed herein are multivalent and multispecific binding proteins, methods of making the binding proteins, and their uses in the diagnosis, monitoring, inhibition, prevention and/or treatment of cancers, tumors, and/or other angiogenesis-dependent diseases characterized by aberrant DLL4 and/or VEGF expression or activity.

This invention is directed to a stable liquid pharmaceutical formulation comprising a high concentration, e.g. 50 mg/ml or more, of antibody in about 20-60 mM succinate buffer or 30-70 mM histidine buffer, having pH from about pH 5.5 to about pH 6.5, about 0.01-0.1% polysorbate, and a tonicity modifier that contributes to the isotonicity of the formulation. This liquid formulation is stable at refrigerated temperature (2-8&#xb0; C.) for at least 1 year, and preferably 2 years. This liquid formulation is suitable for subcutaneous injection. The preferred antibodies include Daclizumab, a humanized anti-IL-2 receptor monoclonal antibody; HAIL-12, a humanized anti-IL-12 monoclonal antibody; HuEP5C7, a humanized anti-L selectin monoclonal antibody; and Flintozumab, a humanized anti-gamma interferon monoclonal antibody.

Stable aqueous pharmaceutical formulations of daclizumab antibodies

Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions

This invention is directed to a stable lyophilized pharmaceutical formulation prepared by lyophilizing an aqueous formulation comprising a high concentration, e.g. 50 mg/ml or more, of an IgG antibody in about 5-25 mM histidine buffer having pH from about 5.5 to about 6.5, about 0.005%-0.03% polysorbate, sucrose, and optionally serine, and/or mannitol. This lyophilized formulation is stable at room temperature for at least 6 months, and preferably 1 year. This lyophilized formulation has a short reconstitution time of less than 2 minutes, and is suitable for parenteral administration such as intravenous, intramuscular, intraperitoneal, or subcutaneous injection. This invention is exemplified by the anti-IL2 receptor antibody.

Stable lyophilized pharmaceutical formulation of IgG antibodies

Growing community of inventors

Sunnyvale, CA, United States of America

Supriya Gupta